ALK and lung carcinoma: Furthermore, transformation into SCLC can occur in anaplastic lymphoma kinase (ALK)-positive lung cancer upon treatment with ALK-inhibitors and in wild-type EGFR or ALK NSCLC following immunotherapy [80, 81].